Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Depreciation & Amortization (CF) (2016 - 2025)

Neurocrine Biosciences' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 3.23% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $26.0 million, up 10.64%, while the annual FY2025 figure was $26.0 million, 10.64% up from the prior year.
  • Depreciation & Amortization (CF) reached $6.4 million in Q4 2025 per NBIX's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.7 million in Q3 2025 to a low of $2.5 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $4.7 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 52.38% in 2024, then decreased 1.56% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.0 million in 2021, then grew by 30.0% to $3.9 million in 2022, then grew by 25.64% to $4.9 million in 2023, then grew by 26.53% to $6.2 million in 2024, then grew by 3.23% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Depreciation & Amortization (CF) are $6.4 million (Q4 2025), $6.7 million (Q3 2025), and $6.3 million (Q2 2025).